A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Closed

Abbreviated Title

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy<br />

Status Notes

This study is closed to accrual effective September 16, 2024.

Closed

09/16/2024

Participants

CTSU

Research committees

Leukemia

Eligibility Criteria Expand/Collapse

Eligibility Criteria: SWOG has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.

Other Clinical Trials

SWOG Clinical Trial Number

CTSU/A042001

A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults with Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Research Committee(s)

Leukemia

Activated

02/27/2023

Open

Phase

SWOG Clinical Trial Number

S1925

A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.

Research Committee(s)

Leukemia

Lymphoma

Symptom Control and Quality of Life

Activated

12/14/2020

Accrual

49%

Open

Phase

SWOG Clinical Trial Number

CTSU/AALL1821

A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse

Research Committee(s)

Leukemia

Activated

12/04/2020

Open